A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06146660
·
clinicaltrials.gov ↗
RECRUITING
Status
600
Enrollment
INDUSTRY
Sponsor class
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
DRUG:
Mavacamten
Sponsor
Bristol-Myers Squibb